Boehringer Ingelheim Press Releases

Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology

Positive first half-year 2011 for Boehringer Ingelheim – new growth from innovative medicines /Pradaxa approved in Europe

Breakthrough therapy PRADAXA® (dabigatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial fibrillation in EU

First novel blood thinner in 50 years for the prevention of strokes caused by common heart rhythm disorder, approved in EU

Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives CHMP recommendation for approval

Stroke prevention: "It is time to act"

Boehringer Ingelheim and Ashoka’s Changemakers
Launch "Making More Health" Competition

New data for linagliptin* show clinically meaningful efficacy similar to glimepiride but with fewer cardiovascular events

Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe

Global stroke prevention awareness initiative draws two million votes around the world

Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health"

Boehringer Ingelheim extends "one stop shop" service with new fill and finish capabilities

New data confirm superior blood pressure reductions in diabetic patients treated with TWYNSTA® compared to amlodipine alone

Boehringer Ingelheim and Zealand Pharma enter into a licence and collaboration agreement to advance novel compounds to treat Type-2 diabetes and obesity

Boehringer Ingelheim/Pfizer position regarding the recent publication by Singh et. al., in British Medical Journal, June 15, 2011

Actress Jane Seymour's appeal generates over one million votes to help prevent atrial fibrillation-related strokes

Metacam® now on the FEI "List of Detection Times"

FDA approves linagliptin tablets for the treatment of type 2 diabetes